The government has highlighted the British Business Bank’s largest direct private-company investment, fund commitments for life sciences and deep tech, and reviews of regulation and corporate reporting. It also cites expanded long-term finance capacity.
The diagnosis behind it is more interesting than the measures. Britain is repeatedly said to be good at creating companies and bad at scaling and keeping them.
The business thought
If that diagnosis is right, it favours businesses solving later-stage constraints: specialist talent, large pilots, export finance and patient capital. Those are harder markets to serve and less crowded for exactly that reason.
It also implies the early-stage support market is well served, which anyone selling into it will recognise.
The practical watch
A financing plan should match the company’s physics rather than the fashion. Deep tech needs milestone-based, patient capital and will be damaged by anything else.
Asset-light software may do better on customer-funded growth and disciplined sales efficiency than on a round it does not need. Raising money is not a milestone.
Related reading
- The £1bn playbook: how the Good Growth Fund spends, and how to be on the receiving end
- The UK Budget leaned into scale-up finance, procurement and AI adoption
- Expanded EMI, EIS and VCT limits strengthened the founder-finance toolkit
Source: UK scale-up growth package.